Long Shortz with AROA Biosurgery: A chance at a smoother recovery from a Mastectomy? Thanks Enivo
Stockhead’s Ashtyn Hiron sits down with AROA Biosurgery (ASX:ARX) CEO Dr. Brian Ward to get the short end of the long story on the company’s latest news.
Aroa Biosurgery’s Enivo system may reduce secondary complications in mastectomies, with positive results emerging from its pilot clinical trial of the device showing promise in the all-important management of dead space. Dead space refers to the open space created by surgical separation or excision of soft tissue.
The system could change how patients are treated post-operation but could ask be utilised in other surgeries like treating hernias, breast reconstruction, traumas, tumour removal and orthopaedics.
Tune in to hear AROA Biosurgery’s Dr. Brian Ward on how this could be used in other surgeries, how it works and more.
Related Topics

UNLOCK INSIGHTS
Discover the untold stories of emerging ASX stocks.
Daily news and expert analysis, it's free to subscribe.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.